1. Zenas BioPharma faces a class action securities lawsuit for alleged fraud. 2. Investors claim the company overstated its funding capabilities. 3. Class members can seek compensation without upfront costs. 4. Key date: June 16, 2025, to appoint lead plaintiffs. 5. Levi & Korsinsky is a renowned law firm handling the case.
Class action lawsuits often lead to significant financial implications. Historical examples include similar cases that resulted in stock price declines for affected companies.
The lawsuit may result in financial liability affecting stock valuation and investor confidence. Given the potential for significant losses, the investor sentiment is crucial.
The immediate negative sentiment may drive down stock price quickly. Previous stock declines often occur soon after lawsuit announcements.
Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.
The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146939&wire=4
ZBIO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The filed complaint alleges that defendants made false statements and/or concealed that: (1) Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.
If you suffered a loss in Zenas BioPharma, Inc. during the relevant time frame, you have until June 16, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE Levi & Korsinsky, LLP